TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
HemoGenyx Pharmaceuticals Plc ( (GB:HEMO) ) just unveiled an announcement.
Hemogenyx Pharmaceuticals announced the exercise of warrants for 67,371 new ordinary shares, generating £235,799 in subscription monies. The new shares will be admitted to trading on the LSE, increasing the total number of issued shares to 5,361,267, which shareholders should use for determining changes in share capital interests.
More about HemoGenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals is a publicly traded clinical stage biopharmaceutical company headquartered in London, with US subsidiaries in New York City. The company focuses on developing new medicines and treatments for blood and autoimmune diseases, utilizing distinct product candidates and platform technologies for novel product development.
Average Trading Volume: 82,481
Technical Sentiment Signal: Buy
Current Market Cap: £33.85M
See more insights into HEMO stock on TipRanks’ Stock Analysis page.